Theseus Pharmaceuticals, Inc. (THRX)

NASDAQ: THRX · IEX Real-Time Price · USD
5.77
-0.01 (-0.17%)
Sep 27, 2022 4:30 PM EDT - Market closed
-0.17%
Market Cap 223.38M
Revenue (ttm) n/a
Net Income (ttm) -38.17M
Shares Out 38.71M
EPS (ttm) -1.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 35,486
Open 5.80
Previous Close 5.78
Day's Range 5.42 - 6.21
52-Week Range 4.86 - 24.54
Beta n/a
Analysts Buy
Price Target 22.03 (+281.8%)
Earnings Date Aug 11, 2022

About THRX

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. ... [Read more...]

Industry Biotechnology
IPO Date Oct 7, 2021
Employees 26
Stock Exchange NASDAQ
Ticker Symbol THRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for THRX stock is "Buy." The 12-month stock price forecast is 22.03, which is an increase of 281.80% from the latest price.

Price Target
$22.03
(281.80% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Theseus Pharmaceuticals to Participate at Upcoming September Investor Conferences

CAMBRIDGE, Mass., Sept. 6, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer...

3 weeks ago - PRNewsWire

Theseus Pharmaceuticals Announces Business and Pipeline Highlights and Reports Second Quarter 2022 Financial Results

THE-630 Phase 1/2 clinical trial enrolling patients; initial data expected in Q2 2023 Nomination of development candidate for fourth-generation epidermal growth factor receptor (EGFR) inhibitor program ...

1 month ago - PRNewsWire

Theseus Pharmaceuticals to Participate Virtually in Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass. , Aug. 3, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer...

1 month ago - PRNewsWire

Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass. , May 19, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer...

4 months ago - PRNewsWire

Theseus Pharmaceuticals Appoints Don Hayden to Board of Directors

CAMBRIDGE, Mass. , May 18, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer...

4 months ago - PRNewsWire

Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2022 Financial Results

THE-630 Phase 1/2 clinical trial actively enrolling patients with advanced gastrointestinal stromal tumors (GIST); initial data expected in 1H 2023 On track to nominate development candidate for fourth-...

4 months ago - PRNewsWire

Theseus Pharmaceuticals Announces Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (E...

Poster presentation details lead compounds demonstrating activity against EGFR variants that are resistant to all approved EGFR inhibitors Nomination of development candidate expected in Q3 2022; IND ex...

5 months ago - PRNewsWire

Theseus Pharmaceuticals to Participate Virtually in Needham Healthcare Conference

CAMBRIDGE, Mass. , April 5, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients th...

5 months ago - PRNewsWire

Theseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results

CAMBRIDGE, Mass., March 10, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cance...

6 months ago - PRNewsWire

Theseus Pharmaceuticals to Present Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (...

CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer...

6 months ago - PRNewsWire

Theseus Pharmaceuticals to Participate Virtually in SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 9, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients thro...

7 months ago - PRNewsWire

Theseus Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for THE-630 for the Treatment of Advanced Gastroint...

CAMBRIDGE, Mass., Feb. 2, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (Theseus) (NASDAQ: THRX), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients throug...

7 months ago - PRNewsWire

5 Beaten Down Biotech Stocks That Could Bounce Big In 2022

Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout 2021 amid delays in pro...

Other symbols: ACADALBORCKTXERS
9 months ago - Benzinga

Theseus Pharmaceuticals Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results

CAMBRIDGE, Mass., Nov. 15, 2021 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX), a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, develop...

10 months ago - PRNewsWire

Theseus Pharmaceuticals to Participate Virtually in Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 10, 2021 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a biopharmaceutical company focused on improving the lives of cancer patients through the discov...

10 months ago - PRNewsWire